388 Market St #1300, San Francisco, CA 94111, USA

©2018 by Cellastra Inc. Proudly created with Wix.com

 CELLASTRA INC

DELIVERING THE GENETIC CODE TO THE WOUND FOR SCAR-LESS HEALING

 

TARGETING  GLOBAL UNMET NEEDS IN SURGERY, TRAUMA AND  BURN  INJURIES

CELLASTRA NEWS

CELLASTRA INC 12/15/2019

Cellastra announces results from in-vivo transgene expression of proprietary anti-scarring peptide.                             

Preparing for clinical study in burn injuries

San Francisco, CA, December 15, 2019  Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has obtained promising results  for CELLEXA, a proprietary gene vector enabling in-vivo production of a potent anti-scarring peptide.     

                                          READ MORE

CELLASTRA'S STRATEGIC REPORT 01 /01/2020:

TOP GENE THERAPY COMPANIES

LINK 

INVESTOR PRESENTATION JANUARY 2020  LINK

PRESS RELEASES

CELLASTRA INC 07/15/2019

Cellastra announces filing of global patent application for prevention of scars and adhesions.

                                         READ MORE

CELLASTRA INC 06/24/2019

Cellastra announces collaboration with leading academic laboratory in Canada for manufacturing and testing of a novel gene vector programmed for scar prevention.

Preparing for clinical study in burn injuries

                                       READ MORE

CELLASTRA INC 04/04/2019

 

Cellastra announces updates from American Burn Association's Annual Meeting in Las Vegas, April 2-5, 2019

Prof. Folke Sjoberg, Cellastra Scientific Advisory Board Memberawarded to give the Everett Idris Evans Memorial Lecture on frontiers in burn injury treatment

Cellastra prepares for  clinical study in burn injury

                                           READ MORE